Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 174

1.

Universal Testing and Treatment for HIV Infection in Botswana. Reply.

Lockman S, Makhema J, Essex M.

N Engl J Med. 2019 Nov 28;381(22):2180. doi: 10.1056/NEJMc1911065. No abstract available.

PMID:
31774971
2.

High incidence of tuberculosis in the first year of antiretroviral therapy in the Botswana National antiretroviral therapy programme between 2011 and 2015.

Mupfumi L, Moyo S, Shin SS, Wang Q, Zetola N, Molebatsi K, Nnawa J, Kgwaadira BT, Bewlay L, Chebani T, Iketleng T, Mogashoa T, Makhema J, Musonda RM, Essex M, Kasvosve I, Gaseitsiwe S.

AIDS. 2019 Dec 1;33(15):2415-2422. doi: 10.1097/QAD.0000000000002363.

PMID:
31764106
3.

Molecular characterization of hepatitis C virus in liver disease patients in Botswana: a retrospective cross-sectional study.

Bhebhe L, Anderson M, Souda S, Choga WT, Zumbika E, Shaver ZM, Mbangiwa T, Phinius BB, Banda CC, Melamu P, Musonda RM, Essex M, Blackard JT, Moyo S, Gaseitsiwe S.

BMC Infect Dis. 2019 Oct 22;19(1):875. doi: 10.1186/s12879-019-4514-1.

4.

Self-reported risky sexual practices among adolescents and young adults in Botswana.

Chakalisa U, Wirth K, Bennett K, Kadima E, Manyake K, Gaolathe T, Bachanas P, Marukutira T, Lebelonyane R, Dryden-Peterson S, Butler L, Mmalane M, Makhema J, Roland ME, Pretorius-Holme M, Essex M, Lockman S, Powis KM.

South Afr J HIV Med. 2019 Jun 26;20(1):899. doi: 10.4102/sajhivmed.v20i1.899. eCollection 2019.

5.

Low rates of nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor drug resistance in Botswana.

Moyo S, Gaseitsiwe S, Zahralban-Steele M, Maruapula D, Nkhisang T, Mokaleng B, Mohammed T, Ditlhako TR, Bareng OT, Mokgethi TP, van Widenfelt E, Pretorius-Holme M, Mine MO, Raizes E, Yankinda EK, Wirth KE, Gaolathe T, Makhema JM, Lockman S, Essex M, Novitsky V.

AIDS. 2019 May 1;33(6):1073-1082. doi: 10.1097/QAD.0000000000002166.

6.

PANGEA-HIV 2: Phylogenetics And Networks for Generalised Epidemics in Africa.

Abeler-Dörner L, Grabowski MK, Rambaut A, Pillay D, Fraser C; PANGEA consortium.

Curr Opin HIV AIDS. 2019 May;14(3):173-180. doi: 10.1097/COH.0000000000000542.

7.

Inferring HIV-1 transmission networks and sources of epidemic spread in Africa with deep-sequence phylogenetic analysis.

Ratmann O, Grabowski MK, Hall M, Golubchik T, Wymant C, Abeler-Dörner L, Bonsall D, Hoppe A, Brown AL, de Oliveira T, Gall A, Kellam P, Pillay D, Kagaayi J, Kigozi G, Quinn TC, Wawer MJ, Laeyendecker O, Serwadda D, Gray RH, Fraser C; PANGEA Consortium and Rakai Health Sciences Program.

Nat Commun. 2019 Mar 29;10(1):1411. doi: 10.1038/s41467-019-09139-4.

8.

Global and regional molecular epidemiology of HIV-1, 1990-2015: a systematic review, global survey, and trend analysis.

Hemelaar J, Elangovan R, Yun J, Dickson-Tetteh L, Fleminger I, Kirtley S, Williams B, Gouws-Williams E, Ghys PD; WHO–UNAIDS Network for HIV Isolation Characterisation.

Lancet Infect Dis. 2019 Feb;19(2):143-155. doi: 10.1016/S1473-3099(18)30647-9. Epub 2018 Nov 30.

PMID:
30509777
9.

Molecular characterization of hepatitis B virus in blood donors in Botswana.

Choga WT, Anderson M, Zumbika E, Moyo S, Mbangiwa T, Phinius BB, Melamu P, Kayembe MK, Kasvosve I, Sebunya TK, Blackard JT, Essex M, Musonda RM, Gaseitsiwe S.

Virus Genes. 2019 Feb;55(1):33-42. doi: 10.1007/s11262-018-1610-z. Epub 2018 Oct 31.

PMID:
30382563
10.

Cross-sectional estimates revealed high HIV incidence in Botswana rural communities in the era of successful ART scale-up in 2013-2015.

Moyo S, Gaseitsiwe S, Mohammed T, Pretorius Holme M, Wang R, Kotokwe KP, Boleo C, Mupfumi L, Yankinda EK, Chakalisa U, van Widenfelt E, Gaolathe T, Mmalane MO, Dryden-Peterson S, Mine M, Lebelonyane R, Bennett K, Leidner J, Wirth KE, Tchetgen Tchetgen E, Powis K, Moore J, Clarke WA, Lockman S, Makhema JM, Essex M, Novitsky V.

PLoS One. 2018 Oct 24;13(10):e0204840. doi: 10.1371/journal.pone.0204840. eCollection 2018.

11.

Molecular Characterization of Near Full-Length Genomes of Hepatitis B Virus Isolated from Predominantly HIV Infected Individuals in Botswana.

Anderson M, Choga WT, Moyo S, Bell TG, Mbangiwa T, Phinius BB, Bhebhe L, Sebunya TK, Lockman S, Marlink R, Kramvis A, Essex M, Musonda RM, Blackard JT, Gaseitsiwe S.

Genes (Basel). 2018 Sep 7;9(9). pii: E453. doi: 10.3390/genes9090453.

12.

In Silico Analysis of Hepatitis B Virus Occult Associated Mutations in Botswana Using a Novel Algorithm.

Anderson M, Choga WT, Moyo S, Bell TG, Mbangiwa T, Phinius BB, Bhebhe L, Sebunya TK, Makhema J, Marlink R, Kramvis A, Essex M, Musonda RM, Blackard JT, Gaseitsiwe S.

Genes (Basel). 2018 Aug 21;9(9). pii: E420. doi: 10.3390/genes9090420.

13.

Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study.

Zash R, Jacobson DL, Diseko M, Mayondi G, Mmalane M, Essex M, Gaolethe T, Petlo C, Lockman S, Holmes LB, Makhema J, Shapiro RL.

Lancet Glob Health. 2018 Jul;6(7):e804-e810. doi: 10.1016/S2214-109X(18)30218-3. Epub 2018 Jun 4.

14.

Correction: Immunological non-response and low hemoglobin levels are predictors of incident tuberculosis among HIV-infected individuals on Truvada-based therapy in Botswana.

Mupfumi L, Moyo S, Molebatsi K, Thami PK, Anderson M, Mogashoa T, Iketleng T, Makhema J, Marlink R, Kasvosve I, Essex M, Musonda RM, Gaseitsiwe S.

PLoS One. 2018 Jun 1;13(6):e0198711. doi: 10.1371/journal.pone.0198711. eCollection 2018.

15.

Chronic and Occult Hepatitis B Virus Infection in Pregnant Women in Botswana.

Mbangiwa T, Kasvosve I, Anderson M, Thami PK, Choga WT, Needleman A, Phinius BB, Moyo S, Leteane M, Leidner J, Blackard JT, Mayondi G, Kammerer B, Musonda RM, Essex M, Lockman S, Gaseitsiwe S.

Genes (Basel). 2018 May 17;9(5). pii: E259. doi: 10.3390/genes9050259.

16.

Undisclosed antiretroviral drug use in Botswana: implication for national estimates.

Moyo S, Gaseitsiwe S, Powis KM, Pretorius Holme M, Mohammed T, Zahralban-Steele M, Yankinde EK, Maphorisa C, Abrams W, Lebelonyane R, Manyake K, Sekoto T, Mmalane M, Gaolathe T, Wirth KE, Makhema J, Lockman S, Clarke W, Essex M, Novitsky V.

AIDS. 2018 Jul 17;32(11):1543-1546. doi: 10.1097/QAD.0000000000001862.

17.

Prevalence of Rilpivirine and Etravirine Resistance Mutations in HIV-1 Subtype C-Infected Patients Failing Nevirapine or Efavirenz-Based Combination Antiretroviral Therapy in Botswana.

Diphoko T, Gaseitsiwe S, Kasvosve I, Moyo S, Okatch H, Musonda R, Wainberg M, Makhema J, Marlink R, Novitsky V, Essex M.

AIDS Res Hum Retroviruses. 2018 Aug;34(8):667-671. doi: 10.1089/AID.2017.0135. Epub 2018 Jun 12.

18.

Similar HIV protection from four weeks of zidovudine versus nevirapine prophylaxis among formula-fed infants in Botswana.

Powis KM, Lockman S, Ajibola G, Hughes MD, Bennett K, Leidner J, Batlang O, Botebele K, Moyo S, van Widenfelt E, Makhema J, Petlo C, Jibril HB, McIntosh K, Essex M, Shapiro RL.

South Afr J HIV Med. 2018 Mar 28;19(1):751. doi: 10.4102/sajhivmed.v19i1.751. eCollection 2018.

19.

Effect of Gestational Age at Tenofovir-Emtricitabine-Efavirenz Initiation on Adverse Birth Outcomes in Botswana.

Zash R, Rough K, Jacobson DL, Diseko M, Mayondi G, Mmalane M, Essex M, Petlo C, Lockman S, Makhema J, Shapiro RL.

J Pediatric Infect Dis Soc. 2018 Aug 17;7(3):e148-e151. doi: 10.1093/jpids/piy006.

20.

Immunological non-response and low hemoglobin levels are predictors of incident tuberculosis among HIV-infected individuals on Truvada-based therapy in Botswana.

Mupfumi L, Moyo S, Molebatsi K, Thami PK, Anderson M, Mogashoa T, Iketleng T, Makhema J, Marlink R, Kasvosve I, Essex M, Musonda RM, Gaseitsiwe S.

PLoS One. 2018 Jan 31;13(1):e0192030. doi: 10.1371/journal.pone.0192030. eCollection 2018. Erratum in: PLoS One. 2018 Jun 1;13(6):e0198711.

Supplemental Content

Loading ...
Support Center